CO6660433A2 - Posologia y administración de composiciones basadas en glucocorticoides - Google Patents

Posologia y administración de composiciones basadas en glucocorticoides

Info

Publication number
CO6660433A2
CO6660433A2 CO12201668A CO12201668A CO6660433A2 CO 6660433 A2 CO6660433 A2 CO 6660433A2 CO 12201668 A CO12201668 A CO 12201668A CO 12201668 A CO12201668 A CO 12201668A CO 6660433 A2 CO6660433 A2 CO 6660433A2
Authority
CO
Colombia
Prior art keywords
glucocorticoid
administration
based compositions
posology
replacement
Prior art date
Application number
CO12201668A
Other languages
English (en)
Inventor
Thomas Hedner
Ulrika Sigrida Helena Simonsson
Gudmundur Johannsson
Hans Lennernas
Stanko Skrtic
Original Assignee
Duocort Pharma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42953726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6660433(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Duocort Pharma Ab filed Critical Duocort Pharma Ab
Publication of CO6660433A2 publication Critical patent/CO6660433A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G01N33/743—Steroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se encuentra relacionada a un método mejorado para la administración de composiciones basadas en glucocorticoides, en terapias de reemplazo de glucocorticoides, que posibilitan un régimen basado de forma objetiva para permitir la administración correcta de dosis individuales de glucocorticoides que conlleven a una terapia de reemplazamiento optimizada y de esta manera a una mejora en los resultados a largo plazo para pacientes con insuficiencia renal crónica o temporal.
CO12201668A 2010-05-20 2012-11-08 Posologia y administración de composiciones basadas en glucocorticoides CO6660433A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201000442 2010-05-20

Publications (1)

Publication Number Publication Date
CO6660433A2 true CO6660433A2 (es) 2013-04-30

Family

ID=42953726

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12201668A CO6660433A2 (es) 2010-05-20 2012-11-08 Posologia y administración de composiciones basadas en glucocorticoides

Country Status (15)

Country Link
US (2) US20130209565A1 (es)
EP (1) EP2571505B1 (es)
JP (1) JP2013526552A (es)
KR (1) KR20130099815A (es)
CN (1) CN102933218A (es)
AU (1) AU2011254959A1 (es)
BR (1) BR112012029466A2 (es)
CA (1) CA2799820A1 (es)
CL (1) CL2012003152A1 (es)
CO (1) CO6660433A2 (es)
IL (1) IL223000A0 (es)
MX (1) MX337429B (es)
PE (1) PE20131024A1 (es)
SG (2) SG185457A1 (es)
WO (1) WO2011144327A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
GB201119985D0 (en) 2011-11-19 2012-01-04 Diurnal Ltd Treatment of adrenal insufficiency
US10262112B2 (en) * 2013-02-04 2019-04-16 Precera Bioscience, Inc. Prescription decision support system and method using comprehensive multiplex drug monitoring
GB201308933D0 (en) 2013-05-17 2013-07-03 Diurnal Ltd Paediatric composition
WO2015085276A1 (en) * 2013-12-06 2015-06-11 Biogen Idec Ma Inc. Population pharmacokinetics tools and uses thereof
US20160367755A1 (en) * 2015-06-01 2016-12-22 Massachusetts Institute Of Technology System and method for neuroendocrine control
CN107115308B (zh) * 2016-02-23 2021-02-23 天津金耀集团有限公司 一种氢化可的松双相缓释片剂组合物
CN108553436A (zh) * 2018-06-08 2018-09-21 华益药业科技(安徽)有限公司 一种20mg氢化可的松片处方和工艺规程
US20210249136A1 (en) * 2018-08-17 2021-08-12 The Regents Of The University Of California Diagnosing hypoadrenocorticism from hematologic and serum chemistry parameters using machine learning algorithm

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0119848D0 (en) 2001-08-15 2001-10-10 Univ Sheffield Delayed and sustained drug release
SE0401031D0 (sv) * 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
CN102448464A (zh) * 2009-04-07 2012-05-09 杜奥科特药物公司 改进的糖皮质激素疗法

Also Published As

Publication number Publication date
WO2011144327A1 (en) 2011-11-24
SG185457A1 (en) 2012-12-28
EP2571505A1 (en) 2013-03-27
US20150209375A1 (en) 2015-07-30
CN102933218A (zh) 2013-02-13
SG10201506611XA (en) 2015-09-29
MX2012013254A (es) 2013-01-24
KR20130099815A (ko) 2013-09-06
JP2013526552A (ja) 2013-06-24
PE20131024A1 (es) 2013-10-10
US20130209565A1 (en) 2013-08-15
EP2571505B1 (en) 2016-07-06
CA2799820A1 (en) 2011-11-24
MX337429B (es) 2016-03-04
IL223000A0 (en) 2013-02-03
BR112012029466A2 (pt) 2017-03-01
CL2012003152A1 (es) 2013-07-12
AU2011254959A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
CO6660433A2 (es) Posologia y administración de composiciones basadas en glucocorticoides
CY1120929T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
NI201600029A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para el tratamiento de la tos aguda, sub-aguda o crónica.
PH12017501495A1 (en) Dosage regimen of an s1p receptor modulator
CL2017000554A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
CO6382132A2 (es) Tratamiento de pirfenidona para pacientes con funcion hepatica atipica
UY34984A (es) Métodos para tratar o prevenir asma administrando un antagonista de il-4r.
BR112012028136A2 (pt) terapia de combinaçao
NI201400104A (es) Esketamina para el tratamiento de la depresión refractaria al tratamiento o resistente al tratamiento
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
ES2681973T3 (es) Respuesta antitumoral contra autoepítopos modificados
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
NI201500063A (es) Tratamiento de cáncer con pomalidomida en un individuo con daño renal
PE20151079A1 (es) Tratamiento para artritis reumatoide
CR20110243A (es) Tratamiento de pirfenidona para pacientes con función hepática.
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
BR112012030764A2 (pt) métodos para tratamento de distúrbios metotrexato-resistentes com 10-propargil-10-deazaanibopterin
DK2530780T3 (da) Fremgangsmåde til administration af et hybridsystems funktion
CL2016000396A1 (es) Tratamiento contra el mieloma múltiple
BR112014006942A8 (pt) Método e sistema de comunicação para proporcionar uma resposta de falha devido à perda de conectividade e dispositivo de memória legível por computador
TWD161419S (zh) 針盤
MX2017012449A (es) Tratamiento del dolor.
UY34496A (es) Formulacion nasal
BR112013026606A2 (pt) sistema e método para administrar torneios
BR112013019479A2 (pt) parafuso fosfatado

Legal Events

Date Code Title Description
FC Application refused